Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#111 / 200 Total
PIXY - ShiftPixy Inc - Stock Price Chart
CompanyShiftPixy Inc
IndustryStaffing & Employment Services
Market Cap13.25MEPS (ttm)-73.32
P/E-EPS this Y93.59%
Forward P/E-EPS next Y4.24%
PEG-EPS past 5Y33.72%
P/S0.89EPS next 5Y-
P/B-EPS Q/Q93.89%
Dividend-Sales Q/Q-16.73%
Insider Own72.15%Inst Own0.12%
Insider Trans0.00%Inst Trans-
Short Float6.21%EarningsApr 15
Analyst Recom1.00Target Price4.00
Avg Volume648.74K52W Range1.38 - 76.80
ShiftPixy, Inc. engages in the provision of human capital services. Its services include employment tax processing, human resources and employment compliance, employment related insurance, and employment administrative services solutions. The company was founded by Scott W. Absher and J. Stephen Holmes on June 3, 2015 and is headquartered in Miami, FL.
BEAM - Beam Therapeutics Inc - Stock Price Chart
CompanyBeam Therapeutics Inc
Market Cap2.04BEPS (ttm)-1.78
P/E-EPS this Y-176.27%
Forward P/E-EPS next Y-0.05%
PEG-EPS past 5Y5.58%
P/S5.66EPS next 5Y-3.70%
P/B2.24EPS Q/Q9.51%
Dividend-Sales Q/Q-69.39%
Insider Own6.65%Inst Own78.66%
Insider Trans-16.46%Inst Trans-0.68%
Short Float17.99%EarningsMay 07/b
Analyst Recom1.86Target Price49.50
Avg Volume1.34M52W Range16.95 - 49.50
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Simon AmyChief Medical OfficerApr 02 '24Sale30.5416,530504,85170,060Apr 03 07:43 PM
Evans John M.CEOApr 01 '24Sale32.1318,102581,6171,058,343Apr 03 07:36 PM
Simon AmyChief Medical OfficerApr 01 '24Sale32.137,157229,95486,590Apr 03 07:43 PM
Burrell Terry-AnnChief Financial OfficerApr 01 '24Sale32.125,446174,92670,137Apr 03 07:39 PM
Ciaramella GiuseppePresidentApr 01 '24Sale32.124,534145,632169,616Apr 03 07:33 PM
EGRX - Eagle Pharmaceuticals Inc - Stock Price Chart
CompanyEagle Pharmaceuticals Inc
IndustryDrug Manufacturers - Specialty & Generic
Market Cap58.20MEPS (ttm)0.91
P/E4.92EPS this Y-
Forward P/E-EPS next Y-
PEG1.82EPS past 5Y-3.56%
P/S0.23EPS next 5Y2.70%
P/B0.23EPS Q/Q153.33%
Dividend-Sales Q/Q-12.80%
Insider Own12.02%Inst Own81.49%
Insider Trans0.00%Inst Trans-1.44%
Short Float9.46%Earnings-
Analyst Recom3.00Target Price17.00
Avg Volume147.16K52W Range3.21 - 23.52
May-22-24 09:00AM Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq (GlobeNewswire) -12.81%
Apr-30-24 08:00AM Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting (GlobeNewswire)
Apr-15-24 07:00AM Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida (GlobeNewswire) +13.29%
Apr-12-24 04:05PM Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K (GlobeNewswire)
Feb-05-24 09:55AM Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman (GlobeNewswire)
Feb-01-24 04:05PM Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman (GlobeNewswire)
Jan-26-24 12:33PM EGRX STOCKHOLDERS: Robbins LLP Reminds Eagle Pharmaceuticals Shareholders of Pending Lead Plaintiff Deadline February 9, 2024 (GlobeNewswire)
Jan-24-24 09:45AM EAGLE PHARMACEUTICALS SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Jan-18-24 06:50AM Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio (GlobeNewswire)
Jan-12-24 10:12AM Eagle Pharmaceuticals (EGRX) Tells SEC It Improperly Accounted for Past Two Quarters and Defaults on Lender Agreement - Hagens Berman (GlobeNewswire)
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tarriff ScottCEONov 02 '23Sale13.8710,694148,326545,447Nov 03 04:39 PM
Tarriff ScottCEONov 01 '23Sale13.8210,925150,984556,141Nov 03 04:39 PM
Graves MichaelDirectorOct 27 '23Option Exercise4.949,36046,23810,360Oct 31 05:41 PM
Tarriff ScottCEOOct 03 '23Sale14.4610,734155,174567,066Oct 04 05:07 PM
Tarriff ScottCEOOct 02 '23Sale15.239,511144,853577,800Oct 04 05:07 PM
GRALV - GRAIL Inc. - Stock Price Chart
CompanyGRAIL Inc.
IndustryDiagnostics & Research
Market Cap579.39MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S5.78EPS next 5Y-
Dividend-Sales Q/Q36.00%
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume576.95K52W Range12.51 - 23.36
GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. GRAIL, LLC was formerly known as PSC15, Inc. and changed its name to GRAIL, LLC in January 2016. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, LLC operates as a subsidiary of Illumina, Inc.
YTRA - Yatra Online Inc - Stock Price Chart
CompanyYatra Online Inc
IndustryTravel Services
Market Cap83.19MEPS (ttm)-0.06
P/E-EPS this Y355.53%
Forward P/E-EPS next Y-
PEG-EPS past 5Y30.71%
P/S1.63EPS next 5Y-
P/B1.16EPS Q/Q-
Dividend-Sales Q/Q-11.03%
Insider Own25.70%Inst Own39.80%
Insider Trans0.00%Inst Trans1.87%
Short Float0.10%EarningsMay 30/a
Analyst Recom1.00Target Price4.00
Avg Volume211.65K52W Range1.07 - 2.67
Yatra Online, Inc. engages in the business of selling travel products and solutions. It operates through the following segments: Airline Tickets, Hotel and Holiday Packages, and Other Services. The Airline Tickets segment consists of the sale of airline tickets as well as airline tickets sold as part of the holiday package. The Hotel and Holiday Packages refers to the sales of hotel rooms and travel packages. The Other Services segment includes rail tickets, bus tickets, taxi rentals, and ancillary value-added services. The company was founded by Dhruv Shringi, Manish Amin, and Sabina Chopra in 2005 and is headquartered in Gurgaon, India.
TRSG - Tungray Technologies Inc - Stock Price Chart
CompanyTungray Technologies Inc
IndustryMetal Fabrication
Market Cap60.99MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
Dividend-Sales Q/Q-
Insider Own85.28%Inst Own-
Insider Trans0.00%Inst Trans-
Short Float0.98%Earnings-
Analyst Recom-Target Price-
Avg Volume310.18K52W Range2.60 - 11.78
Tungray Technologies, Inc. is a holding company, which engages in the provision of customized industrial manufacturing solutions to original equipment manufacturers in the semiconductors, printers, electronics, and home appliances sectors. The company was founded by Wanjun Yao on June 1, 2022 and is headquartered in Singapore.
ALLK - Allakos Inc - Stock Price Chart
CompanyAllakos Inc
Market Cap106.25MEPS (ttm)-2.45
P/E-EPS this Y28.45%
Forward P/E-EPS next Y52.82%
PEG-EPS past 5Y0.51%
P/S-EPS next 5Y26.70%
P/B1.02EPS Q/Q-63.58%
Dividend-Sales Q/Q-
Insider Own14.44%Inst Own79.80%
Insider Trans0.00%Inst Trans63.92%
Short Float6.65%EarningsMay 09/a
Analyst Recom2.50Target Price2.90
Avg Volume463.41K52W Range0.98 - 5.64
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.
FOSL - Fossil Group Inc - Stock Price Chart
CompanyFossil Group Inc
IndustryLuxury Goods
Market Cap84.69MEPS (ttm)-2.67
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-111.68%
P/S0.06EPS next 5Y14.90%
P/B0.37EPS Q/Q41.85%
Dividend-Sales Q/Q-21.58%
Insider Own9.09%Inst Own55.06%
Insider Trans0.00%Inst Trans-7.99%
Short Float7.29%EarningsMay 08/a
Analyst Recom4.00Target Price3.75
Avg Volume616.78K52W Range0.75 - 2.92
Fossil Group, Inc. engages in the design, marketing and distribution of consumer fashion accessories. The firm operates through the following geographical segments: Americas, Europe, and Asia. Its products include men's and women's fashion watches, jewelry, handbags, small leather goods, belts, sunglasses, shoes, soft accessories and clothing which are sold through department stores, specialty retail locations, specialty watch and jewelry stores, owned retail and factory outlet stores, mass market stores, owned, and affiliate internet sites. The company was founded by Tom Kartsotis in 1984 and is headquartered in Richardson, TX.
CRDL - Cardiol Therapeutics Inc - Stock Price Chart
CompanyCardiol Therapeutics Inc
IndustryDrug Manufacturers - Specialty & Generic
Market Cap138.00MEPS (ttm)-0.34
P/E-EPS this Y-8.47%
Forward P/E-EPS next Y7.62%
PEG-EPS past 5Y16.52%
P/S-EPS next 5Y-
P/B9.21EPS Q/Q-23.72%
Dividend-Sales Q/Q-
Insider Own4.46%Inst Own9.67%
Insider Trans0.00%Inst Trans-
Short Float0.40%EarningsMay 14/a
Analyst Recom1.00Target Price7.80
Avg Volume491.02K52W Range0.66 - 3.12
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
SKYE - Skye Bioscience Inc - Stock Price Chart
CompanySkye Bioscience Inc
Market Cap235.79MEPS (ttm)-4.50
P/E-EPS this Y82.39%
Forward P/E-EPS next Y-11.87%
PEG-EPS past 5Y32.94%
P/S-EPS next 5Y-
P/B2.99EPS Q/Q86.94%
Dividend-Sales Q/Q-
Insider Own55.17%Inst Own9.28%
Insider Trans0.00%Inst Trans-
Short Float3.07%EarningsMay 29
Analyst Recom1.00Target Price18.33
Avg Volume116.10K52W Range1.44 - 19.41
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.